Pulmonx Corporation
$1.42
▲
3.91%
2026-04-21 07:59:02
pulmonx.com
NMS: LUNG
Explore Pulmonx Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$59.98 M
Current Price
$1.42
52W High / Low
$5.46 / $1.13
Stock P/E
—
Book Value
$1.3
Dividend Yield
—
ROCE
-49.13%
ROE
-77.19%
Face Value
—
EPS
$-1.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
296
Beta
0.19
Debt / Equity
104.15
Current Ratio
5.07
Quick Ratio
4.28
Forward P/E
-1.36
Price / Sales
0.64
Enterprise Value
$44.48 M
EV / EBITDA
-0.84
EV / Revenue
0.49
Rating
None
Target Price
$5.17
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enovis Corporation | $26.27 | — | $1.52 B | — | -0.58% | -58.27% | $37.85 / $21 | $26.05 |
| 2. | Autonomix Medical, Inc. | $0.4 | — | $4.63 M | — | -143.08% | -1.89% | $2.82 / $0.34 | $0.75 |
| 3. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 4. | Axogen, Inc. | $37.23 | — | $2 B | — | -3.96% | -13.49% | $39.99 / $9.22 | $2.73 |
| 5. | Haemonetics Corporation | $61.17 | 16.14 | $2.83 B | — | 10.74% | 19.3% | $87.32 / $47.31 | $19.46 |
| 6. | Profound Medical Corp. | $7.15 | — | $331 M | — | -57.78% | -67.11% | $12.4 / $5.23 | $1.83 |
| 7. | Abbott Laboratories | $93.07 | 25.91 | $162.16 B | 2.6% | 11.47% | 12.96% | $139.06 / $93.92 | $30.02 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 22.6 M | 21.5 M | 23.86 M | 22.54 M | 23.77 M |
| Operating Profit | -9.9 M | -14.39 M | -14.8 M | -14.56 M | -13.42 M |
| Net Profit | -10.43 M | -13.96 M | -15.17 M | -14.45 M | -13.18 M |
| EPS in Rs | -0.25 | -0.33 | -0.36 | -0.34 | -0.31 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 90.5 M | 83.79 M | 68.67 M | 53.66 M |
| Operating Profit | -53.66 M | -57.7 M | -61.94 M | -58.64 M |
| Net Profit | -54 M | -56.39 M | -60.84 M | -58.92 M |
| EPS in Rs | -1.28 | -1.34 | -1.44 | -1.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 129.29 M | 162.85 M | 177.78 M | 193.68 M |
| Total Liabilities | 75.17 M | 77.04 M | 59.47 M | 39.67 M |
| Equity | 54.12 M | 85.81 M | 118.31 M | 154.01 M |
| Current Assets | 101.68 M | 136.25 M | 150.42 M | 168.95 M |
| Current Liabilities | 20.06 M | 24.44 M | 23.16 M | 18.49 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -32.38 M | -31.54 M | -37.61 M | -45.08 M |
| Investing CF | 30.48 M | 17.48 M | -2.01 M | -4.22 M |
| Financing CF | 0.83 M | 1.36 M | 21.4 M | 2.42 M |
| Free CF | -32.83 M | -32.98 M | -38.42 M | -46.4 M |
| Capex | -0.45 M | -1.45 M | -0.81 M | -1.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 8.01% | 22.01% | 27.98% | — |
| Earnings Growth % | 4.24% | 7.31% | -3.26% | — |
| Profit Margin % | -59.67% | -67.3% | -88.6% | -109.8% |
| Operating Margin % | -59.3% | -68.87% | -90.19% | -109.27% |
| Gross Margin % | 74.19% | 74% | 73.9% | 74.29% |
| EBITDA Margin % | -54.33% | -60.74% | -80.8% | -104.34% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.